EQL PHARMA AB (7JK) — Free Cash Flow Generation Index

Latest as of March 2026: -0.03x

EQL PHARMA AB (7JK) has a Free Cash Flow Generation Index of -0.03x as of March 2026. Free cash flow of €-436.00K represents 0% of operating cash flow (€16.79 Million). Explore EQL PHARMA AB capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.

FCF Generation Index

-0.03x
Free Cash Flow / Operating CF

Free Cash Flow

€-436.00K
EUR

Operating Cash Flow

€16.79 Million
EUR

Capital Expenditures

€17.22 Million
EUR

EQL PHARMA AB Free Cash Flow Generation Index (2022–2026)

Historical FCF Generation Index trend for EQL PHARMA AB across 3 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of EQL PHARMA AB.

Annual Free Cash Flow Generation for EQL PHARMA AB (2022–2026)

Year-by-year Free Cash Flow Generation Index for EQL PHARMA AB. Check EQL PHARMA AB cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Year FCG Index Free Cash Flow (EUR) Operating CF Capital Expenditures YoY Change
2026 -1.37x €-38.88 Million €28.36 Million €67.24 Million ▼ -632.7%
2023 0.26x €7.11 Million €27.62 Million €20.51 Million ▼ -45.5%
2022 0.47x €19.74 Million €41.83 Million €22.09 Million
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).